APSR2026-791

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-038
P38
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221227-46904-APSR26_Poster_TRIKORE_AS_433487.pdf
Format: PDF Only
07. COPD
10

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Chin Kook Rhee - Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Seung-Won Ra - Ulsan University Hospital, University of Ulsan College of Medicine Division of Pulmonology, Department of Internal Medicine Ulsan Korea, ROK (South)
Hak-Ryul Kim - Wonkwang University School of Medicine Department of Internal Medicine, Institute of Wonkwang Medical Science Iksan Korea, ROK (South)
Soo-Jung Um - Dong-A University Medical Center, Dong-A University College of Medicine Division of Respiratory Medicine, Department of Internal Medicine Busan Korea, ROK (South)
Kyeongcheol Shin - Yeungnam University Medical Center, Yeungnam University College of Medicine Division of Pulmonology and Allergy, Regional Center for Respiratory Disease Daegu Korea, ROK (South)
Chang Youl Lee - Chuncheon Sacred Heart Hospital, Hallym University College of Medicine Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine Chuncheon Korea, ROK (South)
Benedetta Di Renzo - Chiesi Farmaceutici, S.p.A International Markets Development Division Parma Italy
Alexey Shablakov * Chiesi Farmaceutici, S.p.A International Markets Development Division Parma Italy
Woojin Choi - Kolon Pharma Medical Information Team, Marketing Strategy Division Gwacheon Korea, ROK (South)
Kwang-Ha Yoo - Konkuk University School of Medicine Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
 
 
 
 
 
Presenting Author Details
Alexey
Shablakov
a.shablakov@chiesi.com
+821028198670
31-40
Italy
Trial in Progress (TiP) Abstract
TRIKORE study: A real-world study with fixed triple combination therapy for COPD patients in South Korea
Maximum 25 words
Abstract Content
 
 
 
 
 
 
 
The fixed triple combination beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB), an extrafine formulation in a pressurized metered dose inhaler, is indicated for the maintenance treatment in adult patients with asthma, not adequately treated with inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) and severe chronic obstructive pulmonary disease (COPD), not adequately treated by ICS/LABA or LABA/long-acting muscarinic-antagonist (LAMA). Besides the evidence from the randomized controlled trials, the impact of fixed triple therapy has not been extensively evaluated in a real-world population of COPD patients especially in Asia. TRIKORE is a non-interventional study to assess the effect of BDP/FF/GB for COPD patients in a real-world setting in South Korea. The primary objective is to evaluate the effectiveness after 12-weeks of treatment with BDP/FF/GB on disease status using the CAT total score in COPD patients in South Korea. Secondary endpoints include changes in selected lung function parameters, safety, and adherence to BDP/FF/GB.
TRIKORE is a multi-center (n=15), single-cohort, 12-week observational study with prospective data collection conducted in patients with COPD, aged ≥40 years with a COPD Assessment Test (CAT) total score ≥10, who newly initiated BDP/FF/GB without prior use of single-inhaler triple therapy. As a preliminary analysis, the primary endpoint was evaluated in 167 of the 360 enrolled patients who had completed the 12-week follow-up as of 4 March 2026. Between March 2025 and February 2026, 360 patients with COPD received BDP/FF/GB in TRIKORE study. The mean age was 71.3 years and 83.9% of the patients were male. At baseline, the mean CAT score was 18.5, and post-bronchodilator FEV1 pred% was 63.1%. After 12 weeks, the mean CAT score among 167 patients significantly decreased to 15.9 (mean change from baseline: -2.7; p<0.0001), meeting the minimal clinically important difference of -2.0 points. TRIKORE study is expected to provide clinically relevant evidence about the effectiveness and safety of BDP/FF/GB fixed triple therapy in a real-world COPD patients in South Korea.
No
No
 
JPG or JPEG or PNG format ONLY
COPD, extra-fine, SITT
maximum 3 keywords and no abbreviations, separated by commas
 
341